DRDO issues directions on usage of anti-COVID drug 2-DG
SECTIONS
Last Updated: Jun 01, 2021, 08:40 PM IST
Share
Synopsis
The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May. The first batch of this oral drug, developed by the Defence Research and Development Organisation (DRDO), was released on May 17 by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.
Agencies
The DRDO said the drug is approved for emergency use as adjunct therapy to the standard treatment of COVID-19 patients in the hospital settings.
India News: The DRDO on Tuesday issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing t
Pic credit: ANI
NEW DELHI: The Defence Research and Development Organisation s (DRDO) on Tuesday said that the anti-Covid drug 2DG is
approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings. The DRDO said that anti-Covid drug 2DG can now be given to Covid 19 patients under the care and prescription of doctors. DRDO also issued some important guidelines with regard to its anti-Covid -19 drug. Ideally, 2DG should be prescribed as early as possible by doctors for moderate to severe Covid patients for a maximum duration of up to 10 days, it said.